Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

Inclusion Criteria: * MS patients diagnosed with MS according to the McDonald criteria * MS patients having a relapsing disease course * Being on GA monotherapy (20mg/daily sc) for at least 12 months prior to the standard of care MRI at the time of switch to GA 40mg x 3/weekly * Having standard of care 3T MRI scan while on GA 20mg/daily treatment for at least 12-18 months prior to the start day of the of the GA 40mg x 3/weekly and at the time of switch to GA 40mg x 3/weekly Age over 18 * Pass MRI health screening (in case of EGFR \<59, the contrast will not be applied) * None of the exclusion criteria Exclusion Criteria: * Patients who had a relapse within 30 days prior to MRI scan date * Patients who received steroid treatment within 30 days prior to the MRI scan date * Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study * MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the 12 months prior to start of GA 40mg 3/weekly (e.g., IFN-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.)